New AvidXchange Report Shows Finance Teams More Prepared Than in 2020—But Still Investing to Weather Uncertainty
The survey of 709 finance professionals reveals a key shift: 67% feel more prepared to handle today's economic uncertainty than they did in 2020, crediting increased technology investment and hard-earned experience. Many are continuing to double down on digital tools to stay agile amid inflation, supply chain disruptions, and ongoing market volatility.
Economic Concerns Still Weigh Heavily
While confidence is growing, post-Covid hangover remains. 86% of finance professionals express concern about the current state of the economy, with nearly half taking actions like cutting discretionary spending. Additionally, 50% say they are 'very concerned' about the likelihood of a recession, and 22% expect one to hit within the next 12 months.
Tariffs and inflation are also reshaping financial planning:
83% report supplier cost increases due to inflation
52% say tariffs have led to moderate forecast adjustments
Nearly 1 in 3 organizations are sharing those costs with customers
These findings reflect a market still in flux—and the pressure on finance leaders to respond swiftly and strategically.
Technology Fuels Financial Readiness
Despite uncertainty, tech investments are enabling confidence. Seven in 10 finance professionals say technology is critical to their ability to respond to changing conditions, and 72% say tools implemented early in the pandemic are paying off today.
In fact, 49% say they are more likely to invest in AI and automation specifically because of ongoing economic uncertainty. Top areas of focus include:
AI and machine learning (48%)
Data security and compliance tools (44%)
Collaboration and workflow tools (36%)
Finance teams are embracing technology not just to cut costs—but to enable smarter, faster decisions.
Finance Professionals Emerge as Strategic Partners
The survey findings point to a fundamental shift in how finance is viewed: from operational support to strategic leadership.
Nearly 30% of teams are conducting scenario planning and financial modeling, while 27% are focused on strengthening supplier relationships—clear signals of a proactive, future-focused mindset.
With better tools and a broader mandate, finance leaders are stepping into roles that directly shape business direction, resilience, and growth.
Momentum in a Shifting Economy
Though 52% of respondents expect volatility to continue into 2026, the overall tone is one of momentum. Finance professionals are moving from reactive to proactive, leaning into their role as stewards of strategy, stability, and innovation.
'Finance teams aren't just adapting—they're planning smarter, automating faster, and driving strategic decisions across the business,' said Dan Drees, President at AvidXchange. 'This research reinforces what we're seeing in the market—technology is a critical enabler for companies looking to drive efficiency and fuel growth.'
To read the full report visit https://www.avidxchange.com/resources/finance-teams-economic-volatility/.
About AvidXchange®AvidXchange (Nasdaq: AVDX) is a leading provider in accounts payable (AP) automation, offering intelligent AP software and payment solutions specifically designed for mid-market businesses and their suppliers. With 25 years of industry experience, AvidXchange modernizes the way businesses manage their expenses and payments by offering AI-enhanced software coupled with support from experts. Empowering over 8,500 growth-driven businesses, AvidXchange increases efficiency, control, and visibility in financial operations and has securely processed payments to more than 1.3 million suppliers through its proprietary payment network over the past five years. For more information, visit avidxchange.com.
Media Contact:Alexis RiddickPublic Relations Managerpr@avidxchange.comInicia sesión para acceder a tu portafolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg and 120 mg Addition of TUS to VEN+AZA improves MRD-negativity rates; 78% among responders 100% CR/CRh in FLT3 wildtype AML, representing 70% of AML population 100% CR/CRh and MRD-negativity rates in TP53, RAS and FLT3-ITD mutated AML Broad spectrum activity and excellent safety profile continue at 120 mg dose to date SAN DIEGO and TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ('Aptose' or the 'Company') (OTC: APTOF, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today provided a data update from the Phase 1/2 TUSCANY trial in newly diagnosed AML. The trial was initiated in December 2024, and the growing body of positive data includes the recently completed third cohort of 120 mg TUS in the TUS+VEN+AZA triplet therapy. Data to date from ten (10) patients across all three cohorts, 40 mg, 80 mg or 120 mg TUS dose in TUS+VEN+AZA, support the use of TUS with standard of care treatment across all AML populations, including those carrying mutations that are the most difficult to treat and those with mutated and unmutated (wildtype) FLT3 genes. The TUS+VEN+AZA triplet is being developed as a safe and well-tolerated mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. At the 120 mg TUS dose level in combination with VEN+AZA, as with the prior reported 40 mg and 80 mg TUS dose cohorts, no significant safety concerns or dose limiting toxicities (DLTs) have been observed in the TUSCANY trial, including no prolonged myelosuppression in Cycle 1 of subjects in remission, no reports of drug-related QTc prolongation or differentiation syndrome (DS), and no treatment-related deaths. Nine out of ten dosed patients remain on study across all dose cohorts and enrollment is being advanced to the 160 mg TUS dose level following the Cohort Safety Review Committee (CSRC) meeting. 'We already have data from three different TUS dose levels in the TUSCANY trial, and the data continue to strengthen at higher doses of TUS and over time. We are building a strong case for TUS+VEN+AZA as a triplet frontline therapy of choice to address a broad AML population, including subgroups with the most adverse of mutations,' said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. Data highlights: Comparison of CR/CRh1 Response rates2-5: VEN+AZA2 TUS+VEN+AZA All subjects 65% 90% (9/10) NPM1-mutant 67% 100% (2/2) FLT3-ITD 61% 100% (2/2) TP53-mutant 52% 100% (2/2) Comparison of MRD-negativity6 rates among All Subjects and among CR/CRh Responders3: VEN+AZA2,3 TUS+VEN+AZA Among All Subjects 23.4% 70% (7/10) Among CR/CRh Responders 40.9% 78% (7/9) Comparison of MRD-negativity rates among more difficult-to-treat Patient Subpopulations defined as Lower Benefit (TP53-mutated) and Intermediate Benefit (FLT3-ITD or RAS-mutated) relative to VEN+AZA5: VEN+AZA3,5 TUS+VEN+AZA Intermediate Benefit 27.9% 100% (3/3) Lower Benefit 14.5% 100% (2/2) TUS+VEN+AZA - CR/CRh and MRD-negativity rates among Subjects with Adverse Mutations: TP53, FLT3-ITD, RAS mutations: Achieved CR/CRh and MRD-negativity 100% (5/5) 'As illustrated in the data highlights, the addition of TUS to VEN+AZA appears to boost response rates and MRD-negativity while maintaining favorable safety and tolerability,' said Rafael Bejar, M.D., Ph.D., Chief Medical Officer of Aptose, 'and the 100% CR/CRh and 100% MRD-negativity rates among the five biallelic TP53-mutant, FLT3-ITD, and RAS-mutant AML cases are exciting to see, as this can correlate with longer overall survival. We have observed a trend towards achieving CRs more quickly at the higher dose levels, so we are keen to see the activity as we advance into the 160 mg TUS dose cohort.' Key messages: Addition of TUS to VEN+AZA demonstrates excellent CR/CRh rates 100% CR/CRh among all subjects treated at 80 mg and 120 mg TUS dose levels Appear to be achieving CR earlier with 120 mg TUS than with 40 mg or 80 mg Addition of TUS to VEN+AZA demonstrates excellent MRD-negativity rates MRD-negativity in 7 of 9 (78%) already achieved in patients who responded to therapy Expect patient survival to be extended with continued long-term treatment Excellent safety and well tolerated with no dose-limiting toxicities (No DLT) at completed dose levels Broad-spectrum activity including patients with adverse TP53, RAS and FLT3-ITD mutations No loss of MRD-negativity observed to date, including in one patient with over 7 months of follow up MRD-negativity and remissions continue to mature over time on therapy No relapses reported to date and no treatment related deaths The only non-responder was a patient at the initial TUS dose level (40 mg) that did not achieve TUS exposures previously associated with response Additional data are included in the new Aptose corporate presentation here. TUSCANY: TUS+VEN+AZA Triplet Phase 1/2 Study The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. The TUSCANY triplet Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by late 2025. Data will be released as it becomes available. More information on the TUSCANY Phase 1/2 study can be found on (here). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential and safety profile of tuspetinib (including the triplet therapy) and its clinical development, the anticipated enrollment rate in the TUSCANY trial and the timing thereof, as well as statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'should', 'would', 'may', and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences PietropaoloCorporate Communications & Investor Relations201-923-2049spietropaolo@ 1 Complete Response / Complete Response with Partial Hematological Recovery2 DiNardo et al. New England Journal of Medicine, August 2020; Volume 383(7):617-629.3 Pratz et al. Journal of Clinical Oncology, December 2021; Volume 40 (8):855-865.4 Othman et. al. Blood Neoplasia; September 2024; Volume 1 (3):1-11.5 Döhner et. al. Blood. 2024 November 21;144(21):2211-2222.6 MRD-negative indicates that the amount of Measurable Residual Disease, as assessed by central flow cytometry, is such that the proportion of leukemic cells in a bone marrow sample falls below <0.1%Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
The Apache Software Foundation Announces Apache Ozone 2.0.0
First object store to support operational databases, now with major usability and compatibility enhancements Wilmington, DE, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Apache Software Foundation (ASF), the global home of open source software the world relies on, today announced Apache Ozone 2.0.0, a major milestone for the cloud-native distributed object store built for big data, analytics, and AI workloads. "Apache Ozone 2.0.0 represents years of community collaboration and production lessons from large-scale deployments,' said Sammi Chen, Apache Ozone PMC Chair and Principal Engineer at Cloudera. 'We're seeing growing adoption of Ozone in production, and this release brings the stability, performance, and ecosystem integration users have asked for." Ozone 2.0.0 responds to growing demand from organizations building AI and analytics platforms that require scalable, fault-tolerant, and cost-efficient storage—without giving up on performance or operational ease. Key Highlights of Apache Ozone 2.0.0: Operational Database Support: Apache Ozone is the first object store to support Apache HBase, enabling low-latency read/write workloads alongside traditional object storage. Atomic Key Operations: Support for atomic key overwrite and key replacement improves consistency for applications running concurrently. Modernized Recon UI: The Ozone Recon monitoring interface has been redesigned for clarity, with better metrics and navigation to support administrators. Expanded Platform Support: Now compatible with JDK 17 and JDK 21, and builds natively on ARM64, enabling broader deployment options. Improved Snapshots: Snapshot operations are more robust and efficient, particularly in large-scale environments with frequent replication or churn. Day-2 Operations: SCM decommissioning is now supported, making it easier to safely remove or rotate hardware as part of lifecycle management. With version 2.0.0, Apache Ozone continues its evolution from an object store for Apache Hadoop to a modern, cloud-native storage platform designed for AI, data lakehouses, and hybrid cloud use cases. For more information on Apache Ozone 2.0.0 and to get started, visit Additional Resources: Download: Documentation: Blog: GitHub: Follow on X/Twitter: @ApacheOzone About The Apache Software Foundation (ASF)The Apache Software Foundation (ASF) is the global home for open source software, powering some of the world's most ubiquitous software projects including Apache Airflow, Apache Camel, Apache Cassandra, Apache Groovy, Apache HTTP Server, and Apache Kafka. Established in 1999, the ASF is at the forefront of open source innovation, setting industry standards to advance software for the public good. Learn more at ASF's annual Community Over Code event is where open source technologists convene to share best practices and use cases, forge critical relationships, and learn about advancements in their field. © The Apache Software Foundation. 'Apache' is a registered trademark or trademark of the Apache Software Foundation in the United States and/or other countries. All other brands and trademarks are the property of their respective Brian Proffitt press@ Vice President, Marketing & Publicity The Apache Software FoundationError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Awarity Makes the Inc. 5000 List for the 3rd Consecutive Year, Ranking at #2424
FRISCO, Texas--(BUSINESS WIRE)--Inc. revealed today that Awarity ranks No. 2424 on the 2025 Inc. 5000, its annual list of the fastest-growing private companies in America. The list provides a data-driven snapshot of the most successful companies within the economy's most dynamic segment—its independent, entrepreneurial businesses. Awarity's rapid growth has validated our mission to make world-class advertising accessible to everyone. Share 'Awarity's rapid growth has validated our mission to make world-class advertising accessible to everyone. We thank the businesses that have trusted us with their marketing, seeking better ways to attract new customers via premium advertising channels. It's a testament to our team, whose commitment to small businesses turns premium, effective advertising into an affordable reality,' said Aditya Varanasi, Founder and CEO. 'The most exciting part is what's next. We're developing more channels, an AI-driven customer insights engine, and campaign performance measurement like marketing mix modeling, previously reserved for enterprises.' This marks Awarity's third consecutive year on the list. Founded in 2016, Awarity's mission is to bring advanced advertising technology, once reserved for large corporations, to businesses of any size. Today, Awarity provides access to channels including Banner ads, Connected TV, Meta ads, and Amazon Prime Video— all in one easy platform. 'Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision,' says Mike Hofman, editor-in-chief of Inc. 'These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy.' About Awarity Awarity's mission is to democratize advertising by making it easy, efficient, and affordable for businesses of all sizes to build targeted awareness. Our highly efficient advertising platform reaches your target customer on top channels including Banner ads, Connected TV, Meta ads, and Amazon Prime Video, all through one intuitive platform. About Inc. Media Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. For more information, visit
